Three developments involving GLP-1 drugs surfaced this week, and together they touch both the legal and clinical sides of this medication class. Two new lawsuits target Novo Nordisk's business practices around its GLP-1 products, while Eli Lilly's oral GLP-1 candidate cleared a major testing milestone. If you take or are considering a GLP-1 medication, these events may shape what is available to you and how it is priced.
This case, filed by Ferrie, names Novo Nordisk as the defendant and centers on how the company handles its GLP-1 drugs. The court filing is pending, and the specific allegations have not yet been made public. That means readers cannot yet know whether the suit concerns manufacturing, marketing, patient access, or something else tied to these medications. Until more details emerge, this remains one to watch rather than one to draw conclusions from. I would suggest checking back as the case moves forward, since early filings often reveal little about the eventual claims.
This second suit adds to the legal pressure Novo Nordisk faces this week, though it raises a different set of questions than the Ferrie case. As with the Ferrie case, the substance of the allegations has not been disclosed yet, so it is not possible to say what specific practices are being challenged. Pricing and marketing lawsuits in this drug class can affect what patients pay out of pocket or how insurers cover these medications, depending on the outcome. Because two separate suits against the same company surfaced close together, it may signal broader scrutiny of Novo Nordisk's GLP-1 business practices, though that is not yet confirmed by the filings themselves.
Unlike the two lawsuits, this development comes from the research and testing side of GLP-1 drugs. Eli Lilly's daily pill, known as orforglipron, has now finished Phase 3 testing for adults with type 2 diabetes who have not achieved adequate blood sugar control through diet and exercise alone. Completing Phase 3 is typically the last major testing stage before a drug company seeks regulatory approval, and the results from this trial are now posted publicly. For patients, a daily pill option could offer an alternative to the injectable GLP-1 drugs currently on the market, though approval and availability would still need to follow before that becomes a reality.
For now, the two lawsuits against Novo Nordisk remain in early stages, and their specific claims are not yet part of the public record. If you take a Novo Nordisk GLP-1 product, it may be worth checking back on these cases as more details come out, since court filings often clarify the underlying issues over time. On the treatment side, orforglipron's completed Phase 3 trial is a step toward possible approval, but it is not yet available to patients. I would suggest talking with your doctor about your current GLP-1 treatment options rather than waiting on a pill that has not yet reached the market.
Key details
A lawsuit filed by Ferrie accuses Novo Nordisk of improper GLP-1 drug practices.
Hunter's lawsuit targets Novo Nordisk's pricing and marketing tactics for GLP-1 drugs.
Orforglipron, Eli Lilly's daily GLP-1 pill, completed Phase 3 testing with results posted.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-09-02
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.